How GLP-1 drugs are reshaping heart care

The story of GLP-1 drugs has moved at pace. These medicines first became established in clinical practice to help manage diabetes, and then gained widespread attention as weight-loss treatments.

More recently, another strand of evidence has come to the fore: they may also offer cardiovascular protection in ways that were not fully anticipated.

A major review underlines this change in perspective. By pooling findings from large clinical trials, it highlights a consistent trend: these medicines do more than influence metabolism – they lower the risk of serious cardiovascular outcomes.

From blood sugar to heart care

When clinicians initially prescribed drugs such as semaglutide and liraglutide, the focus was controlling blood glucose. Weight reduction then became a prominent driver for use.

Over time, however, trials began reporting fewer heart attacks and strokes among people taking these medicines.

That repeated signal prompted a key question: were the heart-related gains simply a knock-on effect of better weight and glucose control, or were the drugs benefiting the cardiovascular system more directly?

A decade of evidence

A team at Anglia Ruskin University examined 11 major trials carried out between 2016 and 2025. Altogether, the studies involved 91,490 participants and tracked outcomes for an average of around 2.7 years.

Only robust trials were included. Each had at least 3,000 participants and lasted for a minimum of one year, helping the reviewers set aside weaker evidence and concentrate on dependable longer-term results.

“This is the most comprehensive review to date of long-term cardiovascular outcome trials for GLP-1 receptor agonists,” said Dr. Simon Cork, lead author of the study.

“We know that one of the factors that weighs on people’s minds when considering going onto these drugs is the potential long-term side effects.”

Lower risk of major heart events

The review’s primary endpoint was major adverse cardiovascular events, a combined measure covering cardiovascular death, heart attack and stroke.

Across the analysis, people taking GLP-1 drugs experienced a 14 percent lower rate of these events than those given a placebo.

While 14 percent can sound modest in isolation, applied across very large patient populations it could translate into a substantial number of avoided, life-changing outcomes.

Reduced deaths and heart problems

The improvements were not limited to the main combined endpoint. Deaths from cardiovascular causes were 13 percent lower, and deaths from any cause were also reduced by 13 percent.

Non-fatal heart attacks and non-fatal strokes each fell by 15 percent, and hospital admissions for heart failure dropped by 12 percent.

Importantly, these patterns appeared repeatedly across different trials, and that consistency increases confidence that the effect is real.

“Our results show that, when taken over a prolonged period of at least one year, these medications do much more than help control blood sugar or weight,” Cork said.

“They significantly reduce the risk of heart attacks, strokes and premature death in people who are already vulnerable.”

Not just weight loss

A central issue is whether cardiovascular benefits can be explained solely by weight reduction or improved glucose control. The evidence suggests that is not the whole story.

In the SELECT trial, participants had obesity but did not have diabetes, yet they still experienced comparable cardiovascular gains.

Even after the reviewers removed the SELECT trial from the pooled analysis, the overall results remained strong, pointing towards mechanisms beyond metabolic changes alone.

Drugs act directly on the heart

Findings from laboratory work help explain how this might happen. GLP-1 receptors are found in heart tissue and in parts of the nervous system involved in cardiovascular regulation.

Animal studies indicate these drugs can enhance blood-vessel function and dampen inflammation, while also affecting heart rate and vascular health.

Taken together, this supports a two-pronged effect: improved metabolic health alongside direct actions on the cardiovascular system.

Semaglutide stands out

When the data were examined more closely, trials of semaglutide showed slightly larger benefits, with the reduction in risk appearing greater than for the drug class overall.

However, this was a secondary analysis rather than a pre-specified plan, so it needs additional research before any firm conclusions are drawn.

Long-term safety is a central issue for any ongoing treatment, and the review offers encouraging reassurance.

Rates of severe low blood sugar were similar in the treatment and placebo groups, which fits with the way these medicines work: they stimulate insulin release only when glucose levels are elevated.

Concerns about pancreatitis also were not supported by strong signals of increased risk, with event rates remaining low across the included studies.

Digestive side effects

The most common downside is gastrointestinal upset. Nausea, vomiting and diarrhoea were reported more often among people taking these drugs.

For some, symptoms were mild and short-lived; for others, side effects contributed to stopping the medication. Dose adjustments and longer-acting formulations can help some patients tolerate treatment.

Strong and consistent trial evidence

Overall, most of the trials assessed in the review were judged to have a low risk of bias. Using standard quality-assessment tools, the researchers found results that broadly aligned across studies.

When a single trial with minor concerns was removed from the analysis, the main conclusions stayed the same.

“We found the benefits to be consistent across different drugs, trial designs and patient groups,” Cork said.

“This has important implications for clinical practice and health policy, particularly given cardiovascular disease is the leading cause of death in the UK.”

Beyond diabetes care

Taken together, the findings may change how GLP-1 drugs are used. Rather than being reserved for diabetes management or weight loss alone, clinicians may increasingly view them as options for cardiovascular prevention.

Starting treatment earlier in people at high risk could improve outcomes, and using them alongside other therapies may provide additional benefit.

Even so, there are practical barriers. In many places, the cost remains high. Supply has also struggled to keep up with demand, and awareness of the cardiovascular benefits is still developing.

A shifting role for GLP-1 drugs

GLP-1 drugs have effectively passed through three stages of use: first as diabetes medicines, then as weight-loss treatments.

Now they are moving into cardiovascular medicine, and current evidence suggests this third role could prove the most consequential.

“These drugs have the potential to become a key part of healthcare strategies, especially for people with type 2 diabetes or established heart disease,” Cork said.

“Using them earlier and more widely across populations could help prevent thousands of serious cardiovascular events.”

The evidence is strong enough to open up new questions: how early should treatment begin, which patients gain the most, and can costs fall enough to support broader access?

For now, one message is clear. These medicines are no longer only about glucose or weight; they are increasingly part of a wider shift in how heart disease is prevented and treated.